Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Dyax receives FDA guidance on BLA pathway for DX-88

Sep. 4, 2006

Sankyo and Ajinomoto sign license agreement for diabetes compound AJD-101

Sep. 4, 2006

ChemDiv and Yale receive NIH grant for adrenal gland disorder research

Sep. 1, 2006

SBIR grant to support Velcura's research into processes in bone formation

Sep. 1, 2006

Obesity drug candidate BVT-74316 enters phase I testing

Sep. 1, 2006

Novel treatment options for metabolic disorders described in recent patents

Sep. 1, 2006

Chrysalin fails to meet primary endpoint in fracture repair

Aug. 31, 2006

Gestiva recommended for approval to prevent preterm birth

Aug. 30, 2006

Recent patents describe new treatment strategies for diabetes

Aug. 30, 2006

Ingested SIRS effective in preclinical models of type 1 diabetes and EAE

Aug. 30, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...